Endocrine Abstracts

Glucagon-Like Peptide 1 receptor agonists (GLP1RAs) have been shown to lower the risk of cardiovascular events and death in people with type 2 diabetes at high cardiovascular risk. Danuglipron, is a small molecule peptide agonist of the GLP1 receptor, a novel drug class of oral medication with promising effects on improving glycaemic control and promoting weight loss in people with diabetes or obesity. Due to the early cardiovascular risk reduction observed in some GLP1RA card...